Inside the research

Haemonetics Corporation

HAE Research profile · latest available data

Price overview

$105.30

▼ -0.70 (-0.7%)

52w hi$108.80
52w lo$47.67
Vol492.60K
As of25 Sep 2026

The Verdict

Buy

Our score +0.53

Short+0.57
Medium+0.64
Long+0.21

computed 2026-09-27

Key fundamentals

Haemonetics Corporation

Healthcare · Medical Devices

Market cap$4.79B
Enterprise value$5.74B
Trailing P/E50.87x
Forward P/E18.23x
EV / EBITDA16.00x
P / S (ttm)3.54x
Profit margin7.1%
Return on equity11.2%
Revenue growth+5.6%
Earnings growth+2.9%
Debt / equity140.26

Layer Breakdown

LayerRawContribution
Fundamental+0.15
Sector+0.08
Technical+0.43
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

United States · www.haemonetics.com

Risk Metrics

Beta vs SPX0.57
Corr SPX0.19
Annual vol46.8%
Annual ret+27.9%
Sharpe0.60
Max DD-49.0%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-06Earnings Release, Exhibitsread
2026-07-28Officer / Director Change, Shareholder Vote…read
2026-06-05Reg FD Disclosure, Exhibitsread
2026-05-07Earnings Release, Exhibitsread
2026-05-01Officer / Director Changeread
2026-03-03Reg FD Disclosureread
2026-02-12Reg FD Disclosureread
2026-02-05Earnings Release, Exhibitsread
2026-01-09Other Material Event, Exhibitsread
2025-11-06Earnings Release, Exhibitsread
2025-08-07Earnings Release, Exhibitsread
2025-07-25Shareholder Voteread

Insider Trades

DateInsiderRoleActionSharesValue
2026-07-24Madaus Martin DGrant2.54K—
2026-07-24Zane Ellen MGrant2.54K—
2026-07-24Pomeroy ClaireGrant2.54K—
2026-07-24KROLL MARK WGrant2.54K—
2026-07-24Johnson Lloyd EmersonGrant2.54K—
2026-07-24COYLE MICHAEL JGrant2.54K—
2026-07-24Bryant Diane MGrant2.54K—
2026-07-24ABERNATHY ROBERT EGrant2.54K—
2026-06-05Maunsell Farris MaryanneVP, Chief Accounting OffiWithheld for tax259$18.46K
2026-06-05Miller Laurie A.SVP, Human ResourcesWithheld for tax313$22.31K

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders0
Top-5 share0.0%
HHI0 (—)

SEC Filings

DateFormDoc
2026-08-0610-Qview
2026-08-068-Kview
2026-07-284view
2026-07-284view
2026-07-283view
2026-07-284view
2026-07-284view
2026-07-284view
2026-07-284view
2026-07-284view
2026-07-284view
2026-07-288-Kview
2026-06-09DEFA14Aview
2026-06-09ARSview
2026-06-09DEF 14Aview

The Long Run

FY 2010–2025 · 15 years

LineLatestCAGRTrend
Revenue$1.36B+9.6%
Gross profit$615.10M+5.1%
Operating income$164.88M+5.6%
Net income$115.40M+6.2%
Cash from ops$181.75M+2.8%

Indices

S&P MidCap 400

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$105.72$106.58$104.71$105.30492.60K
Sep 24$106.67$108.22$105.92$106.00416.80K
Sep 23$108.56$110.28$106.70$106.82704.90K
Sep 22$109.26$110.14$108.38$108.52446.60K
Sep 21$109.24$110.06$108.05$108.73327.00K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →